A Separation Matrix and a Method of Separating Antibodies
The invention discloses a separation matrix comprised of porous spherical particles to which antibody-binding protein ligands have been covalently immobilized, wherein the density of said ligands is in the range of 10.5-15 mg/ml and the volume-weighted median diameter of said particles is in the range of 30-55 μm. The invention further discloses a method of separation of antibodies by affinity chromatography which employs the said separation matrix within a chromatography column.
1 . A separation matrix comprising porous spherical particles to which antibody-binding protein ligands have been covalently immobilized, wherein the density of said ligands is above 10 mg/ml and the volume-weighted median diameter of said particles is in the range of 30-55 μm.
2 . The separation matrix of claim 1 , wherein the density of said ligands is in the range of 10.5-15 mg/ml, such as 11-15 mg/ml.
3 . The separation matrix of claim 1 , wherein said porous spherical particles comprise a crosslinked polysaccharide.
4 . The separation matrix of claim 1 , wherein said porous spherical particles comprise crosslinked agarose.
5 . The separation matrix of claim 4 , wherein the agarose has been allylated before gelation.
6 . The separation matrix of claim 1 , wherein said porous spherical particles have a gel phase distribution coefficient, expressed as K D for dextran of molecular weight 110 kDa, of 0.6-0.8, such as 0.6-0.7.
7 . The separation matrix of claim 1 , wherein said ligands comprise an Fc-binding protein.
8 . The separation matrix of claim 7 , wherein said Fc-binding protein is Protein A.
9 . The separation matrix of claim 1 , wherein said ligands comprise monomers, dimers or multimers of Protein A domains.
10 . The separation matrix of claim 9 , wherein one or more of said domains have been mutated.
11 . The separation matrix of claim 10 , wherein one or more of said domains is derived from Protein Z or the B or C domain of Protein A and wherein the amino acid residue at position 23 is a threonine.
12 . The separation matrix of claim 9 , wherein one or more of said domains comprises an amino acid sequence as defined by SEQ ID NO: 8 or 9.
13 . The separation matrix of claim 9 , which after 5 hours incubation in 0.5 M NaOH at 20+/−2° C. retains at least 95% of its original binding capacity.
14 . A chromatography column comprising the separation matrix according to claim 9 .
15 . The chromatography column of claim 14 , comprising a packed bed of said separation matrix, wherein said packed bed has a bed height of up to 5 or 10 cm, such as 2-5 cm or 2-4 cm.
16 . A chromatography system comprising a plurality of chromatography columns according to claim 14 .
17 . The chromatography system of claim 16 , arranged for performing continuous chromatography.
18 . The chromatography system of claim 16 , comprising at least two, such as at least three, chromatography columns, packed with the same separation matrix and connected with one or more connecting lines such that liquid can flow from one column to a subsequent one and from a last column to a first column and wherein each connecting line between two columns comprises at least one on/off valve.
19 . A method of separation of antibodies by affinity chromatography, which method comprises the steps of:
a) conveying a process feed through at least a first chromatography column according to claim 14 , to adsorb antibodies from said feed;
b) optionally washing said first chromatography column;
c) conveying an eluent through said first chromatography column to elute antibodies; and
d) recovering said eluent with antibodies.
20 . The method of claim 19 , which is carried out in a chromatography system comprising a plurality of chromatography columns, wherein each column comprises porous spherical particles to which antibody-binding protein ligands have been covalently immobilized, wherein the density of said ligands is above 10 mg/ml and the volume-weighted median diameter of said particles is in the range of 30-55 μm.
21 . The method of claim 19 , wherein:
in step a) an effluent from said first chromatography column is passed through a second chromatography column packed with the same separation matrix as the first column;
after step a), in a step a′), the process feed is redirected to the second chromatography column and an effluent from the second chromatography column is passed through a third chromatography column packed with the same separation matrix as the first and second columns;
after step a′), in a step a″), the process feed is redirected to the third chromatography column and an effluent from the third chromatography column is passed through the first chromatography column;
step c) is performed before step a″);
after step a′), in a step c′), the eluent is conveyed through the second chromatography column to elute antibodies;
after step a″), in a step c″), the eluent is conveyed through the third chromatography column to elute antibodies; and
the sequence of steps a), a′), a″), c), c′) and c″) is optionally repeated one or more times.
22 . The method of claim 19 , wherein in step a), the residence time is less than 2 min, such as 0.3-1 min or 0.3-0.8 min.
23 . The method of claim 21 , wherein in steps a), a′) and a″), the residence time is less than 2 min, such as 0.3-1 min or 0.3-0.8 min.
24 . The method of claim 19 , wherein said process feed comprises at least 4 mg/ml antibodies, such as 4-15 or 4-10 mg/ml.
25 . The method of claim 21 , further comprising steps e), e′) and e″), after steps c), c′) and c″) respectively, comprising conveying a cleaning liquid through said first, second and third chromatography columns.
26 . The method of claim 25 , wherein said cleaning liquid comprises at least 0.1 M alkali such as NaOH.